Interinstitutional patient transfers between rapid chemotherapy cycles were feasible to utilize proton beam therapy for pediatric Ewing sarcoma family of tumors
| Autor: | Shingo Sakashita, Aiko Sakai, Tomohiko Masumoto, Sho Hosaka, Takashi Fukushima, Toko Shinkai, Ryo Sumazaki, Tomohei Nakao, Hideyuki Sakurai, Yuni Yamaki, Kazuo Imagawa, Masashi Mizumoto, Atsushi Iwabuchi, Kouji Masumoto, Hiroko Fukushima, Ryoko Suzuki, Chie Kobayashi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Vincristine Chemotherapy Ifosfamide Cyclophosphamide business.industry medicine.medical_treatment Original research article medicine.disease 030218 nuclear medicine & medical imaging Radiation therapy 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine Radiology Nuclear Medicine and imaging Sarcoma Adverse effect business Etoposide medicine.drug |
| Popis: | Aim To assess the feasibility of transferring to the University of Tsukuba Hospital for proton beam therapy (PBT) during intensive chemotherapy in children with Ewing sarcoma family of tumors (ESFT) who had been diagnosed and started their first-line treatment at prefectural or regional centers for pediatric oncology. Background The treatment of ESFT relies on a multidisciplinary approach using intensive neoadjuvant and adjuvant chemotherapies with surgery and radiotherapy. Multi-agent chemotherapy comprising vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide (VDC-IE) is widely used for ESFT, and the interval between each course is very important for maintaining the intensity and effect of chemotherapy. Materials and methods Clinical information of patients who received PBT and VDC-IE between April 2009 and May 2016 was collected retrospectively. The intervals between each course of VDC-IE and adverse events were assessed. Results Fifteen patients were evaluated. No delays in the intervals of chemotherapy due to transfer were observed. There were no adverse events caused during/just after transfer and no increases in adverse events. The estimated 4-year overall and event-free survival rates were 94.6% and 84.8%, respectively. Discussion Although the results of efficacy are preliminary, survival rates were comparable with past studies. More experience and follow-up are required to further assess the efficacy of PBT for patients with ESFT. Conclusion Multidisciplinary therapy for children with ESFT involving transfer to our hospital for PBT during VDC-IE was feasible without treatment delay or an increase in adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|